Skip to content

Anesthetic effect of anterior serratus plane block combined with remimazolam on patients undergoing thoracoscopic sympathectomy

Anesthetic effect of anterior serratus plane block combined with remimazolam on patients undergoing thoracoscopic sympathectomy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100049492
Enrollment
Unknown
Registered
2021-08-02
Start date
2021-07-26
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia effect

Interventions

Control group:Serratus anterior plane block was not performed and remimazolam was not administered
Experimental group1:Bilateral serratus anterior plane block with 0.375% ropivacaine was performed under ultrasound guidance 30 min before anesthesia
Experimental group2:Anesthesia was induced by intravenous injection of remimazolam 7 mg, followed by continuous pump injection of 0.2 mg / kg / h
Experimental group3:Bilateral serratus anterior plane block with 0.375% ropivacaine was performed under ultrasound guidance 30 min before anesthesia. And anesthesia was induced by intravenous injectio

Sponsors

The First Affiliated Hospital of Guangxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Aged 16 to 50 years, weight 40-66 kg (BMI 18.5-23.9); 2. ASA classification I~II; 3. Sign the informed consent form with the patient.

Exclusion criteria

Exclusion criteria: 1. Severe heart, lung, liver, kidney dysfunction, abnormal coagulation function; 2. History of drug allergy, history of peptic ulcer, history of depression, history of long-term drinking or drug abuse; 3. There is a recent history of taking opioids; 4. History of postoperative nausea, vomiting or motion sickness; 5. Nausea or vomiting within 48 hours before surgery; 6. Taking psychotropic drugs (benzodiazepines, antidepressants, antiepileptics and antipsychotics).

Design outcomes

Primary

MeasureTime frame
Systolic blood pressure;Diastolic blood pressure;Mean arterial pressure;Heart rate;Pulse oxygen saturation;Incidence of hypotension;Pain score;Use of analgesic drugs;Operation time;Anesthesia time;Anesthesia recovery time;Abnormal conditions such as airway obstruction;Delirium assessment;tumor necrosis factor-a;C reactive protein;Time required to reach an Aldrete improvement score of 9;

Secondary

MeasureTime frame
Time required to reach a post anesthesia discharge scoring system score of 9;Cognitive function assessment;feel sick;

Countries

China

Contacts

Public ContactLu Yizhi

The First affiliated hospital of Guangxi Medical University

175171136@qq.com+86 13457057161

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026